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extracted from a UK primary care database (The Health
Improvement Network). Patients were required to have at least
12 months of data before and after switching. The principle
analysis was the change in HbA1c; secondary analyses included
change in weight and insulin dose. Hypoglycaemia could not be
assessed due to inconsistency in the recording of episodes. Mul-
tivariate analyses were used to adjust for baseline characteristics
and confounding variables. RESULTS: Mean HbA1c levels at
baseline were similar in the T1 and T2 cohorts (8.8% and 8.9%
respectively). After adjustment, both diabetic cohorts showed
statistically signiﬁcant reductions in mean HbA1c 12 months after
switch, by 0.38% (p < 0.001) in T1 and 0.31% (p < 0.001) in T2
patients. Improvement in HbA1c was positively correlated with
baseline HbA1c; patients with baseline HbA1c  8% had reduc-
tions of 0.57% (p < 0.001) and 0.47% (p < 0.001), respectively.
There was no signiﬁcant change in weight or total daily insulin
dose while on glargine. The majority of patients received a basal-
bolus regimen prior to and after switch (mean 79.3% before and
77.2% after switch in T1 patients and 80.4% and 76.8%, respec-
tively in T2 patients, p > 0.05). CONCLUSIONS: In routine
clinical practice, switching from NPH to glargine provides the
opportunity for improving glycaemic control in diabetes patients
inadequately controlled by NPH.
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OBJECTIVES: To investigate the effect on glycaemic control of
switching from a premix-based regimen to a glargine-based
regimen in 528 patients with type 1 (n = 183) or type 2 (n = 345)
diabetes, using unselected primary care data from a UK database
(The Health Improvement Network). METHODS: Patients were
required to have at least 12 months of available data, before and
after switching. The principle analysis was the change in HbA1c;
secondary analyses included change in weight, bolus usage and
insulin dose. Hypoglycaemia could not be assessed due to lack of
consistency in the recording of episodes. Multivariate analyses
were used to adjust for baseline characteristics and confounding
variables. RESULTS: Mean HbA1c levels at baseline were similar
in the T1 and T2 cohorts (9.4% and 9.3% respectively). After
adjustment both cohorts showed signiﬁcant reduction in mean
HbA1c 12 months after the switch: by -0.67% (p < 0.001) in the
T1 cohort and by -0.53% (p < 0.001) in the T2 cohort. Patients
with a baseline HbA1c  10% had the greatest reduction in
HbA1c, by -1.7% (p < 0.001) and -1.2% (p < 0.001), respec-
tively. Proportion of patients receiving a co-bolus prescription
went from 24.6% on premix to 95.1% on glargine in the T1
cohort, p < 0.001 and from 16.2% to 73.9% in the T2 cohort,
p < 0.001. There was no signiﬁcant change in weight in the T2
cohort with a moderate increase in T1 patients (0.3 kg and 3.7 kg
respectively, p > 0.05). Total insulin use (SD) increased in T2
patients (0.67  1.35 IU/Kg to 0.88  1.33 IU/Kg, p < 0.001)
with no signiﬁcant increase in T1 diabetes patients. CONCLU-
SIONS: In everyday practice, patients with T1 or T2 diabetes
inadequately controlled by premix insulins experienced signiﬁ-
cant improvement in glycaemic control over 12 months after
switching to a glargine-based regimen. These ﬁndings support the
use of glargine plus boluses in patients poorly controlled on
premix.
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OBJECTIVES: The control of blood glucose improves the long
term outcomes for patients with type 2 diabetes; this study exam-
ined the levels of glycemic control in a clinic at MSFHCC, Saudi
Arabia. METHODS: Data were obtained from patient medical
records. All patients who met the inclusion criteria: (with type 2
diabetes, made at least four visits during one year, had their
glycated hemoglobin (A1c) level been checked), the time frame
for sampling is 18 months ending in December 2007. Descriptive
statistics, logistics regression, and ANOVA were used in the
analysis. RESULTS: Four hundred nine patients’ records met the
inclusion criteria, male are 64.7% of the sample, the means for
age, A1c, BMI, and the duration of the DM were 53.4, 8.3%,
30.6 and 9.3 years, respectively. A total of 24.9% of the sample
has A1c at the target control level (<7%), the test of differences
of means of age, BMI and Duration of having DM across the
levels of A1c (controlled , not well controlled (7%  A1c < 8.5),
and poorly controlled (A1c  8.5)) did show consistent results
except BMI variable, group at the controlled HbA1c level has
signiﬁcant higher BMI means than the group with poorly con-
trolled A1c level. 13.2% of the sample treated with oral mono-
therapy antidiabetic drugs, 25.6% with a combination of Insulin
and Metformin, and the rest were with multitherapy. In the
logistic regression model, the type of therapy and the duration of
diabetes were signiﬁcant predictors for whether patient has con-
trolled A1c level. CONCLUSIONS: The high rate of uncon-
trolled diabetic patients is an evidence of shortcoming. Large
data might provide much and precise information to explain this
high rate. The unexpected relationship between BMI and A1c
level which noticed in controlled group could be explained by
short duration of diabetes, early aggressive therapy regimens or
other pathophysiological factors. Further follow up of such con-
trolled group may provide an explanation of such relationship.
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OBJECTIVES: We examined glycemic outcomes in patients with
type 2 diabetes (T2D) initiated to insulin glargine (GLAR) or
detemir (DET) using electronic medical records (EMR) from a
specialty practice in Baltimore, US. METHODS: Patients’ EMRs
using GLAR (n = 134) or DET (n = 88) between January 2005–
2007 with at least 4 available clinic visits were evaluated. Each
patient on DET was matched with one or more patients on
GLAR by baseline HbA1c. Average follow-up time was 6 months
RESULTS: Patients were similar in age (59 vs 60 years), HbA1c
(8.65 vs 8.46%), and BMI (33.6 vs 33.7 kg/m2) but differed in
T2D duration (12.9 vs 10years, P = 0.03) and gender (female 58
vs 44%, P = 0.04) between GLAR and DET, respectively. Prior
use of antidiabetic drugs was similar except for a higher percent-
age of patients using premixed insulin in GLAR (24.8% vs 8.9%
[DET], P = 0.004) and of patients using exenatide in DET
(32.9% vs 6.2 % [GLAR], P = 0.0001). Unadjusted A1C values
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were 7.64% for GLAR and 7.87% for DET at the follow-up
visit. After adjusting for baseline characteristics and HbA1c and
concomitant antidiabetic medications during the follow-up
period, A1C remained lower in GLAR versus DET (7.06 vs
7.84%, P = 0.0178). Total insulin dose in GLAR was increased
from 45.3 U to 75.8 U at the follow-up visit and 33.5 U to
48.6 U in DET. Adjusted weight was 101.2 kg for GLAR and
97.1 kg for DET. CONCLUSIONS: Initiation of GLAR relative
to DET in T2D patients is associated with greater improvement
in glycemic control achieved within six months. More exenatide
use in DET relative to GLAR may possibly explain the group
difference in body weight. This analysis was conducted in a single
clinical practice hence further studies are needed to determine
reproducibility of the ﬁndings.
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OBJECTIVES: A meta-analysis of Pioglitazone and Rosiglita-
zone in patients with type 2 diabetes was conducted to evaluate
the effects of each drug on glycemic control, lipids, blood pres-
sure, and weight. In addition, this study was aimed to identify if
there is an ethnic difference in the effects between Asian and
Caucasian patients by subgroup analysis. METHODS: Among
the randomized controlled trials of Pioglitazone or Rosiglitazone
which had been published before February 2008, 63 randomized
controlled trials that were eligible for the inclusion/exclusion
criteria were collected. For quantitative meta-analysis, the
weighted pooled effect sizes and their 95% conﬁdence intervals
were calculated. RESULTS: Glucose lowering effect was higher
in Rosiglitazone, whereas Pioglitazone produced a more favor-
able lipid proﬁle. Both thiazolidinediones demonstrated similar
increases in body weight. The effect on blood pressure was
slightly higher in Pioglitazone. Regarding the effects of Pioglita-
zone, the pooled effect sizes of Pioglitazone 15 mg were very
similar for two different ethnic groups in all parameters. When
the effects of Pioglitazone in Caucasian patients group at dose of
30 mg and Asian patients group at dose of 15 mg were com-
pared, most of the overall effects sizes were higher in Caucasian
patients group than that of Asian patients group. In case of
Rosiglitazone, the pooled effect sizes of Asian patients group
administered 4 mg were higher than Caucasian patients group
administered the same dose. Furthermore, in comparing the
effect sizes of Asian patients group administered 4 mg and Cau-
casian patients group administered 8 mg, the effect sizes were
rather similar than they administered the same dose. CONCLU-
SIONS: The effects of Pioglitazone on the cardiovascular risk
factors are almost the same in different ethnic groups, whereas
those of Rosiglitazone varies with ethnicity. In this regards, well-
designed head-to-head comparative trials as well as long-term
cardiovascular outcome studies should be conducted in order to
accurately determine the various effects of the two thiazolidinedi-
ones on different ethnic groups.
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OBJECTIVES: The objective was to estimate the long-term clini-
cal outcomes in pharmaceutical treatment naïve type 2 diabetes
patients when initiated with biphasic insulin aspart (BIAsp) in a
secondary care setting in urban China. METHODS: A validated
computer simulation model of diabetes (the CORE Diabetes
Model) was used to make long-term projections of clinical out-
comes based on patient characteristics (mean age 49.7 years, time
since diagnosis 1.61 years, HbA1c 9.86%, BMI 24.62 kg.m-2)
and treatment effects of BIAsp (HbA1c improvement of 3.27
percentage points, an increase in hypoglycaemic events of 2.4 per
patient-year). All background and treatment data were obtained
from the Chinese part of the IMPROVE study (n = 7012). Treat-
ment management practices were taken from Chinese urban
hospitals. RESULTS: Superior glycemic control with BIAsp led to
a delay in the onset of diabetes-related complications by 0.31
years (1.16 vs 0.85), e.g. the delay of onset to neuropathy, myo-
cardial infarction and stroke were 1.09, 0.55, and 0.41 years,
respectively. The cumulative incidence of complications was pro-
jected to decrease with BIAsp in the majority of parameters
studied e.g. the incidence of neuropathy was decreased by 9.3%.
Life expectancy increased from 13.62 to 14.05 years. Quality-
adjusted life years (QALYs) (mean  sd) increased by 0.772
(9.01  0.171 vs 8.24  0.146). CONCLUSIONS: The long
term health outcome projections based on surrogate endpoints
reported in the Chinese cohort of the IMPROVE study, indicate
that initiating treatment with BIAsp in treatment naïve (including
OAD naïve) type 2 diabetes patients will improve life expectancy
and quality-adjusted life years, delay the onset of diabetes related
complications, and reduce their cumulative incidence over
patient lifetimes.
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OBJECTIVES: To assess diabetes disease burden and associated
treatment patterns among six European nations. METHODS: A
large multi-country online cross-sectional survey of approxi-
mately 175,000 adults was conducted in 2007 in France,
Germany, Italy, Spain, UK and the The Netherlands by TNS
Healthcare. The survey enabled TNS to build an epidemiological
database based on its proprietary European Healthcare Panel
(EHP) of consumers in these 6 countries. The data is representa-
tive of population gender and age (18–24, 25–34, 35–44, 45–54,
55–64, 65–69 yrs) strata in respective countries, ensured by sam-
pling and intensive panel management. The survey collected
information on select health conditions (incl. diabetes; in the past
12-months) and health care-utilization. RESULTS: Diabetes
disease prevalence varied widely between the 6 nations, as
follows (All pts, Males/Females, proportion type 1/type
2/Gestational/Unknown): Italy: 4%, 5%/3%, 28%/61%/3%/
8%; France: 5%, 5%/4%, 21%/63%/4%/12%; Spain: 5%,
6%/4%, 18%/66%/3%/13%; The Netherlands: 5%, 6%/5%,
13%/84%/1%/1%; Germany: 6%, 6%/5%, 14%/81%/1%/4%;
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